Redwood Bioscience, Inc. develops a protein-chemical engineering technology to produce antibody-drug conjugates and other semi-synthetic biotherapeutics. The company offers SMARTag site-specific protein modification and cytotoxin-linker technologies that enable the generation of homogenous bioconjugates engineered to enhance potency, safety, and stability. Its SMARTag platform provides precise payload positioning and defined stoichiometry of payloadÐprotein ratios. The company was incorporated in 2008 and is based in Emeryville, California. Redwood Bioscience, Inc. operates as a subsidiary of Catalent, Inc.
Redwood Bioscience was acquired by Catalent Pharma Solutions in 2014.
Carolyn Bertozzi, Brian Carlson, Peng Wu, Isaac Carrico, and Jason Rush